Table 4.
Crude prev (%) | ES* weighted population | ES* expected cases | Adjusted prevalence (%) | WHO weighted population | WHO expected cases | Adjusted prevalence (%) | |
---|---|---|---|---|---|---|---|
<15 | – | – | – | ||||
15–19 | 3.6 | 973 | 3 | 3.1 (−0.4–6.6) | 697 | 2 | 2.7 (−1.1–6.8) |
20–24 | 4.3 | 931 | 3 | 3.2 (−0.4–6.9) | 676 | 2 | 3.0 (−1.1–7.1) |
25–29 | 1.6 | 723 | 4 | 5.5 (0.1–10.9) | 652 | 4 | 6.1 (0.1–12.1) |
30–34 | 4.3 | 531 | 3 | 5.6 (−0.7–2.0) | 626 | 3 | 4.8 (−0.6–10.2) |
35–39 | 9.7 | 455 | 5 | 11.0 (1.4–20.6) | 588 | 6 | 10.2 (2.1–18.3) |
40–44 | 6.4 | 392 | 4 | 10.2 (0.3–20.2) | 542 | 6 | 11.1 (2.3–19.9) |
45–49 | 3.8 | 350 | 1 | 2.9 (−2.7–8.4) | 497 | 2 | 4.0 (−1.5–9.6) |
≥50 | 3.2 | 861 | 5 | 5.8 (0.7–10.9) | 1796 | 11 | 6.1 (2.5–9.7) |
Total | 6.0 | 5216 | 28 | 5.4 (3.4–7.4) | 6074 | 36 | 5.9 (4.0–7.9) |